• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Brolucizimab-leading an era of structural revolution for long-term VEGF suppression.

作者信息

Sharma Ashish, Kumar Nilesh, Kuppermann Baruch D, Bandello Francesco

机构信息

Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, India.

Gavin Herbert Eye Institute, University of California, Irvine, CA, USA.

出版信息

Eye (Lond). 2020 Apr;34(4):611-613. doi: 10.1038/s41433-019-0583-z. Epub 2019 Sep 19.

DOI:10.1038/s41433-019-0583-z
PMID:31537892
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7093425/
Abstract
摘要

相似文献

1
Brolucizimab-leading an era of structural revolution for long-term VEGF suppression.布罗鲁单抗——引领长期抑制血管内皮生长因子的结构革命时代。
Eye (Lond). 2020 Apr;34(4):611-613. doi: 10.1038/s41433-019-0583-z. Epub 2019 Sep 19.
2
Evaluation of long-term intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease.评估有和无糖尿病肾病的患者长期玻璃体内抗血管内皮生长因子注射对肾功能的影响。
BMC Nephrol. 2019 Dec 26;20(1):478. doi: 10.1186/s12882-019-1650-1.
3
Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration.雷珠单抗治疗年龄相关性黄斑变性中血管内皮生长因子抑制时间的长期稳定性。
Am J Ophthalmol. 2013 Nov;156(5):989-993.e2. doi: 10.1016/j.ajo.2013.06.020. Epub 2013 Aug 12.
4
High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.美国玻璃体内注射率和医疗保险每注射一次抗血管内皮生长因子支付费用的高度变化。
Ophthalmology. 2016 Jun;123(6):1257-62. doi: 10.1016/j.ophtha.2016.02.015. Epub 2016 Mar 12.
5
Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.玻璃体内抗血管内皮生长因子治疗视网膜血管瘤样增殖的长期视觉预后及预后因素
Graefes Arch Clin Exp Ophthalmol. 2016 Jan;254(1):23-30. doi: 10.1007/s00417-015-2993-3. Epub 2015 Apr 1.
6
A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.新生血管性年龄相关性黄斑变性患者玻璃体内大分子药物动力学的机制模型及雷珠单抗对眼血管内皮生长因子水平的药效学抑制作用
Mol Pharm. 2016 Sep 6;13(9):2941-50. doi: 10.1021/acs.molpharmaceut.5b00849. Epub 2016 Jan 14.
7
Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure.玻璃体内抗血管内皮生长因子药物对角膜、前房和眼压的短期影响。
Cutan Ocul Toxicol. 2019 Dec;38(4):344-348. doi: 10.1080/15569527.2019.1616749. Epub 2019 May 30.
8
Short-term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor-A and pigment epithelium-derived factor in neovascular glaucoma.玻璃体内注射雷珠单抗对新生血管性青光眼患者眼内血管内皮生长因子-A和色素上皮衍生因子浓度的短期影响
Clin Exp Ophthalmol. 2015 Jul;43(5):415-21. doi: 10.1111/ceo.12477. Epub 2015 Jan 14.
9
Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.双眼同一天接受抗血管内皮生长因子玻璃体内注射后的眼内炎发生率。
Am J Ophthalmol. 2018 Oct;194:1-6. doi: 10.1016/j.ajo.2018.06.022. Epub 2018 Jul 6.
10
Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.同一天行双侧玻璃体内抗血管内皮生长因子注射：加拿大一大型视网膜中心的经验。
Ophthalmologica. 2019;242(1):1-7. doi: 10.1159/000499115. Epub 2019 Mar 29.

引用本文的文献

1
Brolucizumab results and adverse visual outcomes study: A single-center real-world Indian experience.布罗利尤单抗疗效及不良视力结局研究：一项单中心印度真实世界经验
Indian J Ophthalmol. 2025 Jun 1;73(6):921-923. doi: 10.4103/IJO.IJO_1897_24. Epub 2025 May 28.
2
Brolucizumab versus Aflibercept in Patients with Diabetic Macular Edema: A Meta-Analysis of Randomized Controlled Trials.布罗鲁单抗与阿柏西普治疗糖尿病性黄斑水肿的疗效比较：一项随机对照试验的荟萃分析
Clin Ophthalmol. 2024 Dec 10;18:3679-3690. doi: 10.2147/OPTH.S487055. eCollection 2024.
3
Brolucizumab in patients with neovascular age-related macular degeneration: Real-life outcomes from a tertiary care eye hospital.Brolucizumab 治疗新生血管性年龄相关性黄斑变性：来自一家三级眼科医院的真实世界研究结果。
Indian J Ophthalmol. 2024 Nov 1;72(Suppl 5):S752-S757. doi: 10.4103/IJO.IJO_562_24. Epub 2024 Sep 10.
4
Exploring Current Molecular Targets in the Treatment of Neovascular Age-Related Macular Degeneration toward the Perspective of Long-Term Agents.从长效药物的角度探索治疗新生血管性年龄相关性黄斑变性的当前分子靶点。
Int J Mol Sci. 2024 Apr 17;25(8):4433. doi: 10.3390/ijms25084433.
5
Vitreous Opacity Following Intravitreal Brolucizumab Injection: A Case Series Review.玻璃体内注射布罗珠单抗后的玻璃体混浊：病例系列回顾
Korean J Ophthalmol. 2024 Apr;38(2):113-121. doi: 10.3341/kjo.2023.0133. Epub 2024 Feb 14.
6
A novel humanized Chi3l1 blocking antibody attenuates acetaminophen-induced liver injury in mice.一种新型人源化Chi3l1阻断抗体可减轻对乙酰氨基酚诱导的小鼠肝损伤。
Antib Ther. 2022 Nov 7;6(1):1-12. doi: 10.1093/abt/tbac027. eCollection 2023 Jan.
7
Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.阿柏西普与 faricimab 在新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿治疗中的比较：综述。
Int J Mol Sci. 2022 Aug 20;23(16):9424. doi: 10.3390/ijms23169424.
8
VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy.用于治疗糖尿病性视网膜病变中视网膜新生血管的 VEGF 靶向药物。
Ann Med. 2022 Dec;54(1):1089-1111. doi: 10.1080/07853890.2022.2064541.
9
Side Effects of Brolucizumab.布罗利尤单抗的副作用。
J Ophthalmic Vis Res. 2021 Oct 25;16(4):670-675. doi: 10.18502/jovr.v16i4.9757. eCollection 2021 Oct-Dec.
10
Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments.经典视网膜药物的分子特征、视网膜治疗靶点及新兴治疗方法
Pharmaceutics. 2021 Jul 20;13(7):1102. doi: 10.3390/pharmaceutics13071102.